Prednisolone phosphate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Prednisolone phosphate
Accession Number
DB14631  (DBSALT002204)
Type
Small Molecule
Groups
Approved, Vet approved
Description
Not Available
Structure
Thumb
Synonyms
  • Prednisolone 21-(dihydrogen phosphate)
  • Prednisolone 21-monophosphate
  • Prednisolone 21-phosphate
Product Ingredients
IngredientUNIICASInChI Key
Prednisolone sodium phosphateIV021NXA9J125-02-0VJZLQIPZNBPASX-OJJGEMKLSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Inflamase Forte Oph Soln 1%Liquid10 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%Solution1 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase MildLiquid.125 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%Liquid1.25 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%Solution / drops0.5 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Orapred ODTTablet, orally disintegrating30 mg/1OralConcordia Pharmaceuticals, Inc2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating15 mg/1OralShionogi2006-06-012016-08-31Us59630 0701 48 nlmimage10 d916ec97
Orapred ODTTablet, orally disintegrating15 mg/1OralConcordia Pharmaceuticals, Inc2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating10 mg/1OralShionogi2006-06-012015-03-31Us
Orapred ODTTablet, orally disintegrating10 mg/1OralConcordia Pharmaceuticals, Inc2006-06-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MillipredSolution10 mg/5mLOralCerecor, Inc.2014-03-01Not applicableUs
MillipredSolution10 mg/5mLOralLaser Pharmaceuticals Llc2009-07-012017-07-03Us
OrapredSolution15 mg/5mLOralShionogi2000-12-142015-10-31Us
PediapredSolution5 mg/5mLOralRoyal Pharmaceuticals2003-03-262018-03-16Us
PMS-prednisolone Sodium Phosphate Ophthalmic Solution ForteSolution1 %OphthalmicPharmascience Inc1992-12-31Not applicableCanada
Prednisolone Sodium PhosphateSolution15 mg/5mLOralA-S Medication Solutions2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralMorton Grove Pharmaceuticals, Inc.2004-10-04Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Prednisolone Sodium PhosphateSolution20 mg/5mLOralBurke Therapeutics2018-06-12Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/1mLOphthalmicButler Animal Health Supply1994-07-29Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.3 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)Solution / dropsOphthalmicRemedy Repack2015-01-20Not applicableUs
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.3 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)Solution / dropsOphthalmicRemedy Repack2016-06-072016-06-08Us
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.3 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)Solution / dropsOphthalmicBauch & Lomb Incorporated1995-12-29Not applicableUs
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.3 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)Solution / dropsOphthalmicNucare Pharmaceuticals,inc.1995-12-29Not applicableUs
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.5 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)SolutionOphthalmicRebel Distributors1995-12-29Not applicableUs
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.3 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)Solution / dropsOphthalmicRpk Pharmaceuticals, Inc.1995-12-29Not applicableUs
Sulfacetamide Sodium and Prednisolone Sodium PhosphatePrednisolone sodium phosphate (2.5 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)SolutionOphthalmicFalcon Pharmaceuticals2004-03-09Not applicableUs
VasocidinPrednisolone sodium phosphate (2.5 mg/1.0mL) + Sulfacetamide sodium (100.0 mg/1.0mL)SolutionOphthalmicNovartis Ophthalmics2007-03-302010-10-13Us
Vasocidin Ophthalmic SolutionPrednisolone sodium phosphate (2.5 mg) + Sulfacetamide sodium (100 mg)SolutionOphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-12-312004-03-24Canada
Vasocidin Ophthalmic SolutionPrednisolone sodium phosphate (2.5 mg) + Sulfacetamide sodium (100 mg)LiquidOphthalmicIolab Pharmaceuticals1992-12-311996-09-09Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pred Phos - BromPrednisolone sodium phosphate (10 mg/1mL) + Bromfenac sodium (0.75 mg/1mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred Phos - GatiPrednisolone sodium phosphate (10 mg/1mL) + Gatifloxacin sesquihydrate (5 mg/1mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred Phos-Gati-BromPrednisolone sodium phosphate (10 mg/1mL) + Bromfenac (0.75 mg/1mL) + Gatifloxacin sesquihydrate (5 mg/1mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Categories
UNII
752SY38R6C
CAS number
302-25-0
Weight
Average: 440.429
Monoisotopic: 440.160004892
Chemical Formula
C21H29O8P
InChI Key
JDOZJEUDSLGTLU-VWUMJDOOSA-N
InChI
InChI=1S/C21H29O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}phosphonic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Prednisolone phosphate.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Prednisolone phosphate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Prednisolone phosphate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Prednisolone phosphate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone phosphate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Prednisolone phosphate.
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Prednisolone phosphate.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Prednisolone phosphate.
4-HydroxytestosteroneThe risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisolone phosphate.
5-androstenedioneThe risk or severity of edema formation can be increased when 5-androstenedione is combined with Prednisolone phosphate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
65064
ChEBI
8379
ChEMBL
CHEMBL1201231
Wikipedia
Prednisolone_sodium_phosphate
AHFS Codes
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentKeratitis, Herpetic / Ocular Herpes Simplex1
4CompletedTreatmentAsthma Acute / Asthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOphthalmic10 mg
SolutionOphthalmic1 %
LiquidOphthalmic.125 %
LiquidOphthalmic1.25 mg
SolutionOral10 mg/5mL
Solution / dropsOphthalmic0.5 %
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral30 mg/1
Tablet, orally disintegratingOral15 mg/1
SolutionOral15 mg/5mL
SolutionOral5 mg/5mL
Solution / dropsOphthalmic10 mg/1mL
SolutionOral25 mg/5mL
Liquid; solution / dropsOphthalmic1 %
Solution / dropsOphthalmic
LiquidOphthalmic
SolutionOphthalmic
SolutionOral20 mg/5mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6221392No2001-04-242018-04-09Us
US6024981No2000-02-152018-04-09Us
US6740341No2004-05-252019-11-24Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.432 mg/mLALOGPS
logP0.92ALOGPS
logP1.15ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)1.18ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area141.36 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity109.37 m3·mol-1ChemAxon
Polarizability43.42 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Glycerone phosphates / Monoalkyl phosphates / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 4 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Hydroxysteroid / Oxosteroid / 11-beta-hydroxysteroid / 17-hydroxysteroid / 11-hydroxysteroid / Delta-1,4-steroid
show 18 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on September 01, 2018 08:40 / Updated on July 13, 2019 01:00